Kaoru Tsuchiya

List of Publications by Year
in descending order

29 papers	1,096 citations	516710 16 h-index	477307 29 g-index
29 all docs	29 docs citations	29 times ranked	1578 citing authors

#	Article	IF	Citations
1	The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy. PLoS ONE, 2022, 17, e0264075.	2.5	2
2	Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma. PLoS ONE, 2022, 17, e0265235.	2.5	4
3	Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers, 2022, 14, 2975.	3.7	5
4	Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. Liver Cancer, 2022, 11, 558-571.	7.7	6
5	The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers, 2021, 13, 2608.	3.7	34
6	Prognosis of intrahepatic cholangiocarcinoma stratified by albumin–bilirubin grade. Hepatology Research, 2021, 51, 902-908.	3.4	11
7	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. Journal of Medical Ultrasonics (2001), 2021, 48, 481-487.	1.3	11
8	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2960-2966.	2.8	36
9	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. International Journal of Molecular Sciences, 2021, 22, 40.	4.1	8
10	Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. Hepatology Research, 2020, 50, 137-143.	3.4	19
11	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatology Research, 2020, 50, 1375-1385.	3.4	22
12	Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. JGH Open, 2020, 4, 1183-1190.	1.6	6
13	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. International Journal of Molecular Sciences, 2020, 21, 3640.	4.1	5
14	Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. Hepatology Research, 2020, 50, 996-999.	3.4	5
15	Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients. Diagnostics, 2020, 10, 173.	2.6	8
16	Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS ONE, 2020, 15, e0231828.	2.5	42
17	Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Scientific Reports, 2019, 9, 10109.	3.3	24
18	Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma–Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers, 2019, 11, 1517.	3.7	30

#	Article	IF	Citations
19	Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. Cancers, 2019, 11, 1256.	3.7	17
20	Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. Journal of Viral Hepatitis, 2019, 26, 893-899.	2.0	25
21	*Wisteria floribunda* agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Hepatology Research, 2018, 48, 1131-1139.	3.4	40
22	Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0154558.	2.5	34
23	Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. Hepatology Research, 2015, 45, E130-40.	3.4	13
24	*Wisteria floribunda* agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatology Research, 2015, 45, E82-8.	3.4	55
25	Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. Hepatology Research, 2015, 45, 667-675.	3.4	26
26	Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver International, 2015, 35, 1581-1589.	3.9	30
27	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer, 2014, 3, 458-468.	7.7	512
28	Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. Journal of Gastroenterology, 2014, 49, 1495-1503.	5.1	44
29	Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. Hepatology Research, 2014, 44, 720-727.	3.4	22